{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:19:38Z","timestamp":1793312378876,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1038\/s41431-021-00848-3","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T09:05:22Z","timestamp":1615799122000},"page":"872-880","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Mainstream genetic testing for breast cancer patients: early experiences from the Parkville Familial Cancer Centre"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9399-0709","authenticated-orcid":false,"given":"Catherine","family":"Beard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Monohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Cicciarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4361-4657","authenticated-orcid":false,"given":"Paul A.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"848_CR1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.5694\/mja13.11218","volume":"199","author":"PA James","year":"2013","unstructured":"James PA, Mitchell G, Bogwitz M, Lindeman GJ. The Angelina Jolie effect. The. Med J Aust. 2013;199:646.","journal-title":"Med J Aust"},{"key":"848_CR2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.5694\/mja17.01124","volume":"209","author":"J Kirk","year":"2018","unstructured":"Kirk J, Barlow-Stewart KK, Poplawski NK, Gleeson M, Tucker K, Friedlander M. Medicare-funded cancer genetic tests: a note of caution. Med J Aust. 2018;209:193\u20136.","journal-title":"Med J Aust"},{"key":"848_CR3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/gim.2016.139","volume":"19","author":"GP Jarvik","year":"2017","unstructured":"Jarvik GP, Evans JP. Mastering genomic terminology. Genet Med. 2017;19:491\u20132.","journal-title":"Genet Med"},{"key":"848_CR4","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/humu.20880","volume":"29","author":"SE Plon","year":"2008","unstructured":"Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29:1282\u201391.","journal-title":"Hum Mutat"},{"key":"848_CR5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med"},{"key":"848_CR6","first-page":"1497","volume":"29","author":"F Poggio","year":"2018","unstructured":"Poggio F, Bruzzone M, Ceppi M, Ponde NF, La Valle G, Del Mastro L, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Annals of oncology: official journal of the European Society for. Med Oncol. 2018;29:1497\u2013508.","journal-title":"Med Oncol"},{"key":"848_CR7","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","volume":"24","author":"A Tutt","year":"2018","unstructured":"Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, et al. Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018;24:628\u201337.","journal-title":"Nat Med"},{"key":"848_CR8","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.2009.22.7991","volume":"28","author":"AW Kurian","year":"2010","unstructured":"Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1\/2 mutation carriers. J Clin Oncol. 2010;28:222\u201331.","journal-title":"J Clin Oncol"},{"key":"848_CR9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl J Med. 2017;377:523\u201333.","journal-title":"N. Engl J Med"},{"key":"848_CR10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1748-717X-5-104","volume":"5","author":"S Heymann","year":"2010","unstructured":"Heymann S, Delaloge S, Rahal A, Caron O, Frebourg T, Barreau L, et al. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol. 2010;5:104.","journal-title":"Radiat Oncol"},{"key":"848_CR11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10689-020-00160-x","volume":"19","author":"EM Grindedal","year":"2020","unstructured":"Grindedal EM, J\u00f8rgensen K, Olsson P, Gravdehaug B, Lur\u00e5s H, Schlichting E, et al. Mainstreamed genetic testing of breast cancer patients in two hospitals in South Eastern Norway. Fam Cancer. 2020;19:133\u201342.","journal-title":"Fam Cancer"},{"key":"848_CR12","doi-asserted-by":"crossref","first-page":"e194428","DOI":"10.1001\/jamanetworkopen.2019.4428","volume":"2","author":"Z Kemp","year":"2019","unstructured":"Kemp Z, Turnbull A, Yost S, Seal S, Mahamdallie S, Poyastro-Pearson E, et al. Evaluation of cancer-based criteria for use in mainstream BRCA1 and BRCA2 genetic testing in patients with breast cancer. JAMA Netw Open. 2019;2:e194428.","journal-title":"JAMA Netw Open"},{"key":"848_CR13","doi-asserted-by":"crossref","DOI":"10.1038\/srep29506","volume":"6","author":"A George","year":"2016","unstructured":"George A, Riddell D, Seal S, Talukdar S, Mahamdallie S, Ruark E, et al. Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. Sci Rep. 2016;6:29506.","journal-title":"Sci Rep"},{"key":"848_CR14","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ygyno.2017.01.030","volume":"145","author":"M Kentwell","year":"2017","unstructured":"Kentwell M, Dow E, Antill Y, Wrede CD, McNally O, Higgs E, et al. Mainstreaming cancer genetics: a model integrating germline BRCA testing into routine ovarian cancer clinics. Gynecologic Oncol. 2017;145:130\u20136.","journal-title":"Gynecologic Oncol"},{"key":"848_CR15","unstructured":"eviQ Cancer Genetics National Reference Committee. Risk Management, 2020, https:\/\/www.eviq.org.au\/cancer-genetics\/adult\/risk-management2020."},{"key":"848_CR16","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/bjc.2013.730","volume":"110","author":"AJ Lee","year":"2014","unstructured":"Lee AJ, Cunningham AP, Kuchenbaecker KB, Mavaddat N, Easton DF, Antoniou AC. BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface. Br J Cancer. 2014;110:535\u201345.","journal-title":"Br J Cancer"},{"key":"848_CR17","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/s41431-019-0390-9","volume":"27","author":"E Tutty","year":"2019","unstructured":"Tutty E, Petelin L, McKinley J, Young MA, Meiser B, Rasmussen VM, et al. Evaluation of telephone genetic counselling to facilitate germline BRCA1\/2 testing in women with high-grade serous ovarian cancer. Eur J Hum Genet: EJHG. 2019;27:1186\u201396.","journal-title":"Eur J Hum Genet: EJHG"},{"key":"848_CR18","doi-asserted-by":"crossref","unstructured":"Nielsen SM, Eccles DM, Romero IL, Al-Mulla F, Balma\u00f1a J, Biancolella M, et al. Genetic testing and clinical management practices for variants in non-BRCA1\/2 breast (and Breast\/Ovarian) cancer susceptibility genes: an international survey by the evidence-based network for the interpretation of germline mutant alleles (ENIGMA) clinical working group. JCO Precis Oncol. 2018;2.","DOI":"10.1200\/JCO.2018.36.15_suppl.1539"},{"key":"848_CR19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/humu.21628","volume":"33","author":"AB Spurdle","year":"2012","unstructured":"Spurdle AB, Healey S, Devereau A, Hogervorst FB, Monteiro AN, Nathanson KL, et al. ENIGMA-evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum Mutat. 2012;33:2\u20137.","journal-title":"Hum Mutat"},{"key":"848_CR20","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10689-019-00122-y","volume":"18","author":"N Hallowell","year":"2019","unstructured":"Hallowell N, Wright S, Stirling D, Gourley C, Young O, Porteous M. Moving into the mainstream: healthcare professionals\u2019 views of implementing treatment focussed genetic testing in breast cancer care. Familial Cancer. 2019;18:293\u2013301.","journal-title":"Familial Cancer"},{"key":"848_CR21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ygyno.2020.05.001","volume":"158","author":"M Gleeson","year":"2020","unstructured":"Gleeson M, Kentwell M, Meiser B, Do J, Nevin S, Taylor N, et al. The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients. Gynecol Oncol. 2020;158:431\u20139.","journal-title":"Gynecol Oncol."},{"key":"848_CR22","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/ajmg.a.37697","volume":"170","author":"CA Beard","year":"2016","unstructured":"Beard CA, Amor DJ, Di Pietro L, Archibald AD. \u201cI\u2019m Healthy, It\u2019s Not Going To Be Me\u201d: exploring experiences of carriers identified through a population reproductive genetic carrier screening panel in Australia. Am J Med Genet Part A. 2016;170:2052\u20139.","journal-title":"Am J Med Genet Part A"}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41431-021-00848-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41431-021-00848-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41431-021-00848-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:02:32Z","timestamp":1684616552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-021-00848-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["848"],"URL":"https:\/\/doi.org\/10.1038\/s41431-021-00848-3","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,15]]},"assertion":[{"value":"5 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}